Mereo BioPharma (MREO) Net Equity Issued and Repurchased (2023 - 2025)
Mereo BioPharma (MREO) posted quarterly Net Equity Issued and Repurchased of $39000.0 for Q4 2025, down 99.66% quarter-over-quarter from $11.6 million in Q3 2023.
Mereo BioPharma (MREO) Net Equity Issued and Repurchased (2023 - 2025) Analysis & Trends
Mereo BioPharma (MREO) has reported Net Equity Issued and Repurchased for 2 consecutive years, with $39000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Net Equity Issued and Repurchased changed N/A year-over-year to $39000.0; the TTM figure through Dec 2025 stood at $39000.0 (down 99.66% YoY), while the FY2025 annual figure was $39000.0, down 99.92% from the prior year.
- Net Equity Issued and Repurchased retreated to $39000.0 in Q4 2025 per MREO's latest filing, from $11.6 million in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $11.6 million in Q3 2023 and bottomed at $39000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Mereo BioPharma | 47.39 Mn | 47.39 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 39,000.00 |
| Dec 31, 2025 | 39,000.00 |
| Sep 30, 2023 | 11.61 Mn |
| Sep 30, 2023 | 11.61 Mn |